10 November 2021 - A top official from the US FDA offered a mixed assessment of the agency’s biosimilars program, noting that although the program is growing, there is more uptake of the program in the oncology space, with less activity in other treatment areas. 

The costly and lengthy process of getting biosimilars approved is also a deterrent to wider uptake.

Read Regulatory Affairs Professional Society article